Diphtheria toxin CRM197
Diphtheria toxin CRM197 structure
|
Common Name | Diphtheria toxin CRM197 | ||
|---|---|---|---|---|
| CAS Number | 92092-36-9 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
| Symbol |
GHS06 |
Signal Word | Danger | |
|
Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer.
Proc. Natl. Acad. Sci. U. S. A. 110(7) , 2517-22, (2013) Globo H (GH) is a hexasaccharide specifically overexpressed on a variety of cancer cells and therefore, a good candidate for cancer vaccine development. To identify the optimal carrier and adjuvant combination, we chemically synthesized and linked GH to a car... |
|
|
Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.
Expert Rev. Vaccines 10(11) , 1621-31, (2011) Conjugate vaccines using diphtheria toxoid variant (CRM(197)), diphtheria toxoid and tetanus toxoid (TT) as carrier protein may induce immune interactions (interference or impairment as measured by lower antibody levels, or enhancement [higher antibody levels... |
|
|
Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.
Anticancer Res. 31(7) , 2483-8, (2011) The therapeutic outcome for T-cell acute lymphoblastic leukemia (T-ALL) remains poor; thus, novel, targeted therapies are urgently needed. Recently, we showed that heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the EGF family... |
|
|
Effect of increased CRM₁₉₇ carrier protein dose on meningococcal C bactericidal antibody response.
Clin. Vaccine Immunol. 19(4) , 551-6, (2012) New multivalent CRM(197)-based conjugate vaccines are available for childhood immunization. Clinical studies were reviewed to assess meningococcal group C (MenC) antibody responses following MenC-CRM(197) coadministration with CRM(197)-based pneumococcal or H... |
|
|
Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice.
Vaccine 30(43) , 6111-4, (2012) Typhoid fever is a public health problem, especially among young children in developing countries. To address this need, a glycoconjugate vaccine Vi-CRM₁₉₇, composed of the polysaccharide antigen Vi covalently conjugated to the non-toxic mutant of diphtheria ... |
|
|
Regulation of cellular growth, apoptosis, and Akt activity in human U251 glioma cells by a combination of cisplatin with CRM197.
Anticancer Drugs 23(1) , 81-9, (2012) The aberrantly activated antiapoptotic phospatidyl-3-inositol-kinase (PI3K)/Akt signaling induced by cisplatin limits the effectiveness of chemotherapy; inhibition of this pathway may augment the sensitivity of tumor cells to cisplatin-induced toxicity and pr... |
|
|
The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer
Biochem. Biophys. Res. Commun. 422(4) , 676-80, (2012) Highlights ► HB-EGF over-expression in A2780/Taxol, A2780/CDDP cells and the matched xenografts. ► CRM197 induces enhanced apoptosis in A2780/Taxol and A2780/CDDP cells. ► CRM197 arrests A2780/Taxol and A2780/CDDP cells at G0/G1 phase. ► CRM197 suppressed the... |
|
|
A novel combined conjugate vaccine: enhanced immunogenicity of bFGF with CRM197 as a carrier protein.
Mol. Med. Report. 4(5) , 857-63, (2011) Tumor growth is partly dependent on tumor-associated angiogenesis, which is regulated by angiogenic growth factors. As the first angiogenic growth factor to be identified, basic fibroblast growth factor (bFGF) plays a major role in angiogensis and tumor growt... |
|
|
Clinical experience of treatment of metastatic melanoma and solid tumours adopting a derivative of diphtheria toxin: cross-reacting material 197.
In Vivo 27(2) , 197-202, (2013) Diphtheria toxin (DT) has shown anticancer activity in both experimental models and humans but its adverse effects stopped further developments. Cross-reacting Material 197 (CRM197) is the product of a single missense mutation (Gly52 to Glu) within fragment A... |
|
|
A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
Anticancer Res. 31(7) , 2461-5, (2011) Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a promising target for cancer therapy. We have already started a phase I study of CRM197, a specific HB-EGF inhibitor, for advanced ovarian cancer. In this study, we evaluated possible cli... |